Litcius/Paper detail

Study the role of bacterial neuraminidase against adenocarcinoma cells in vivo

Shatha M. Ali, Bahaa A. Laftah, Ahmed Majeed Al-Shammari, Hasnain S. Salih

2021AIP conference proceedings30 citationsDOI

Abstract

Biological therapy is opening up a new age for the treatment of cancer. The bacteria -cancer interaction was firstly observed by Busch and Fehleisen (1). To reducing the potential of pathogenicity of using active bacterial, using bacterial products like proteins, enzymes, immune-toxins, that straightaway target malignancy cells and regress the volume of the tumor through expansion inhibition, induction of apoptosis (2). This study was aimed at testing the antiangiogenic bacterial neuraminidase against mammalian adenocarcinoma AN3 transplanted into syngeneic immunocompetent mice through intratumoral injection to determine the antitumor activity in vivo. Histopathological sections for the treated tumor mass demonstrated proliferation of granulation tissue with substantial necrosis region. This study indicated the role of bacterial neuraminidase in reducing the volume of the solid tumor when compared with an untreated group which is a confirmed feature that makes it as anti-tumor agent.

Topics & Concepts

In vivoNeuraminidaseAdenocarcinomaCancer researchMalignancyImmune systemCancerChemistryOncolytic virusCancer cellMicrobiologyEnzymePathologyBiologyImmunologyMedicineBiochemistryBiotechnologyGeneticsCancer Research and TreatmentsNanoplatforms for cancer theranosticsVirus-based gene therapy research
Study the role of bacterial neuraminidase against adenocarcinoma cells in vivo | Litcius